[{"address1": "Darwinweg 24", "city": "Leiden", "zip": "2333 CR", "country": "Netherlands", "phone": "31 71 524 7400", "fax": "31 71 524 7445", "website": "https://www.pharming.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.", "fullTimeEmployees": 382, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sijmen  de Vries M.B.A., M.D.", "age": 64, "title": "President, CEO & Executive Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 1438000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeroen  Wakkerman", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mireille  Sanders M.Sc.", "age": 55, "title": "Chief Operations Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Susanne  Embleton", "title": "Investor Relations Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ruud  Van Outersterp", "age": 59, "title": "Chief Ethics & Compliance Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Anurag  Relan M.D., MPH", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen  Toor", "age": 52, "title": "Chief Commercial Officer & GM Americas", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alexander  Breidenbach M.B.A.", "age": 59, "title": "Chief Business Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruno M. L. Giannetti", "age": 71, "title": "Consultant", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 1, "compensationRisk": 1, "shareHolderRightsRisk": 4, "overallRisk": 1, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.67, "open": 7.485, "dayLow": 7.37, "dayHigh": 7.6, "regularMarketPreviousClose": 7.67, "regularMarketOpen": 7.485, "regularMarketDayLow": 7.37, "regularMarketDayHigh": 7.6, "beta": 0.842, "volume": 4775, "regularMarketVolume": 4775, "averageVolume": 6777, "averageVolume10days": 5680, "averageDailyVolume10Day": 5680, "marketCap": 509629600, "fiftyTwoWeekLow": 6.65, "fiftyTwoWeekHigh": 16.71, "priceToSalesTrailing12Months": 1.836126, "fiftyDayAverage": 8.03236, "twoHundredDayAverage": 10.15228, "currency": "USD", "enterpriseValue": 5020528128, "profitMargins": -0.048010003, "floatShares": 656633420, "sharesOutstanding": 67835400, "sharesShort": 530, "sharesShortPriorMonth": 3504, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "heldPercentInstitutions": 0.00077, "shortRatio": 0.07, "bookValue": 0.326, "priceToBook": 22.60736, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -13325000, "trailingEps": -0.19, "enterpriseToRevenue": 18.088, "enterpriseToEbitda": -996.73, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "PHAR", "underlyingSymbol": "PHAR", "shortName": "Pharming Group N.V.", "longName": "Pharming Group N.V.", "firstTradeDateEpochUtc": 1608733800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "5db69536-7ef9-35ef-8d96-33da6cebf0ca", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.37, "recommendationKey": "none", "totalCash": 160323008, "totalCashPerShare": 0.236, "ebitda": -5037000, "totalDebt": 122024000, "quickRatio": 2.645, "currentRatio": 3.386, "totalRevenue": 277556992, "debtToEquity": 55.23, "revenuePerShare": 4.18, "returnOnAssets": -0.01735, "returnOnEquity": -0.063260004, "freeCashflow": -292000, "operatingCashflow": -5764000, "revenueGrowth": 0.35, "grossMargins": 0.8855, "ebitdaMargins": -0.01815, "operatingMargins": -0.04212, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]